Oral administration of ketamine
Disclosed are pharmaceutical compositions having a portion of ketamine for intraoral release and another ketamine for gastrointestinal release. The compositions can further include aspirin. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine.
1 . A compressed bilayer tablet comprising (a) a first composition comprising a first amount of ketamine and (b) a second composition comprising a second amount of ketamine,
wherein the first composition is chewable and formulated to disintegrate or dissolve intraorally in a subject providing rapid release of the ketamine of the first composition in the subject, and the second composition comprises enteric coating and is formulated to be ingested and released in the gastrointestinal tract of the subject, and wherein the second composition is enclosed within the first composition.
2 . A method of reduction of depression, reduction of fatigue, reduction of suicidality, treatment of asthma, treatment of cannabinoid hyperemesis syndrome exacerbation, or treatment of Alzheimer's disease or dementia in a subject, comprising administering to the subject the pharmaceutical composition of claim 1 .
3 . The pharmaceutical composition of claim 1 , wherein the first composition comprises at least about 20% of the total amount of ketamine in the composition and the second composition comprises at least about 20% of the total amount of ketamine in the composition.
4 . The method of claim 2 , wherein the first composition comprises at least about 20% of the total amount of ketamine in the composition and the second composition comprises at least about 20% of the total amount of ketamine in the composition.
5 . The method of claim 2 , wherein the first composition is chewable.
6 . The method of claim 5 , wherein the second composition is compressed.
7 . The method of claim 6 , wherein the second composition comprises enteric coating.